Form 4: SpringWorks Therapeutics Director Receives Stock Grant

Director Martin Mackay received 10,060 restricted stock units from SpringWorks Therapeutics on May 14, 2025, according to a Form 4 filing.

Summary

• On May 14, 2025, Martin Mackay, a director of SpringWorks Therapeutics, received a grant of 10,060 restricted stock units (RSUs).
• These RSUs were granted under the company's Amended and Restated Non-Employee Director Compensation Policy.
• The RSUs will vest fully on the earlier of May 14, 2026, or the date of the next annual meeting of stockholders, contingent upon continued service to the Issuer.
• Following the transaction, Mackay's holdings include 20,023 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine equity grant to a director, which is generally viewed as a positive sign of aligning interests. There are no indications of negative news or concerns.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

This type of equity grant to non-employee directors is a common practice in publicly traded companies to align their interests with those of shareholders and incentivize their continued service.

Comparison to Industry Standards

• Equity compensation for non-employee directors is a standard practice across the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options and restricted stock units as part of their director compensation packages.
• The specific amount and vesting schedule of the RSUs are likely benchmarked against peer companies of similar size and stage of development as SpringWorks Therapeutics.

Stakeholder Impact

• The equity grant aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.
• The grant has a minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

SpringWorks Therapeutics, Director, RSUs, Stock Grant, Form 4, Martin Mackay, Compensation, Equity